Liquidia Co. (NASDAQ:LQDA) Given Consensus Recommendation of “Buy” by Analysts

Liquidia Co. (NASDAQ:LQDA) has received an average rating of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $25.38.

Several analysts have recently weighed in on LQDA shares. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th.

Liquidia Stock Down 0.3 %

NASDAQ:LQDA opened at $14.82 on Friday. The company has a fifty day moving average of $14.30 and a 200-day moving average of $11.86. The firm has a market capitalization of $1.25 billion, a P/E ratio of -9.09 and a beta of 0.07. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.99.

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the transaction, the insider now directly owns 270,388 shares of the company’s stock, valued at $3,185,170.64. The trade was a 2.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now directly owns 1,019,177 shares in the company, valued at $12,005,905.06. This represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 in the last three months. 30.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC purchased a new position in shares of Liquidia in the 4th quarter worth about $59,000. Summit Investment Advisors Inc. boosted its holdings in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after buying an additional 1,719 shares during the last quarter. Walleye Trading LLC boosted its holdings in shares of Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after buying an additional 4,670 shares during the last quarter. D. E. Shaw & Co. Inc. purchased a new position in shares of Liquidia in the 4th quarter worth about $142,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Liquidia in the 4th quarter worth about $154,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).